Davis Polk advised the underwriter in connection with the $340 million SEC-registered offering of 1,511,546 American depositary shares of BeiGene, Ltd. by certain existing ADS holders. The ADSs are listed on the Nasdaq Global Select Market under the symbol “BGNE.”

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide.

The Davis Polk corporate team included partner Alan F. Denenberg, counsel Jason Bassetti and associates Alex DeGroat and Sherry Tan. The tax team included partner Mario J. Verdolini and associate Ben Levenback. The intellectual property and technology transactions team included partner David R. Bauer and associate Tilak Koilvaram. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post